Naslov
Deep venous thrombosis and kidney disease

Autori
Prkačin, Ingrid ; Bulum, Tomislav ; Svaguša, Tomo ; Golub, A. ; Pikivača, Tamara ; Cavrić, Gordana

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Journal of Hypertension. 2018 ; 36(e-Suppl. 1) / - , 2018, 186-186

Skup
28th European Meeting on Hypertension

Mjesto i datum
Barcelona, Španjolska, 08.06.2018. - 11.06.2018

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
deep venous thrombosis ; kidney disease

Sažetak
Of 3209 p in Emergency Department we identified 65 (2% of all) with simptomatic (pain + edema) limb DVT (upper limb 3p, proximal lower limb 22p + 40 p with DDVT). The mean age was 61.5 years (27–92 years), 70% and 32% had hypertension and diabetes mellitus. 38% atrial fibrillation and no one known malignant disease ; body mass index was 34.4 ± 5.1 kg/m2, eGFR 55 ± 21 mlmin/1.73m2. At baseline 25% had chronic kidney disease: 10% moderate chronic kidney disease (stage 3 CKD) (CrCl 30–59 mL/min), 15% had mild CKD (CrCl 60–89 mL/min). After ultrasound doppler imaging and confirmation of DDVT with positive D-dimer test result, we put p on DOACs. The 3-month administration of DOACs for DVT caused a nonsignificant decrease of eGFR (declined from 55 ± 21 mlmin-11.73m2 to 54 ± 16 mlmin-11.73m2 (p = 0.01)). Control ultrasound imaging after 3 months was associated with recanalisation of DVT, without proximal exstension and no thromboembolic events. In 20% of p with DDVT we found new malignant disease (lung and colon). Kidney dysfunction is common among individuals with DVT. The results of our study suggest that the treatmen of DDVT of the limbs with DOACs in p with kidney dysfunction is safe therapy.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA